𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma

✍ Scribed by David A. Reardon; James J. Vredenburgh; April Coan; Annick Desjardins; Katherine B. Peters; Sridharan Gururangan; Sith Sathornsumetee; Jeremy N. Rich; James E. Herndon; Henry S. Friedman

Publisher
Springer US
Year
2011
Tongue
English
Weight
197 KB
Volume
105
Category
Article
ISSN
0167-594X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of irinotecan plus celeco
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma
✍ David A. Reardon; Jennifer A. Quinn; James Vredenburgh; Jeremy N. Rich; Sridhara πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 219 KB

## Abstract ## BACKGROUND In the current study, the authors report a Phase II trial of irinotecan (CPT‐11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COX‐2 inhibitor, among MG patients with recurrent disease. ## METHODS Patients with MG at any

Phase I study of temozolomide and escala
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma
✍ David N. Korones; Michal Benita-Weiss; Thomas E. Coyle; Laszlo Mechtler; Peter B πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 74 KB

## Abstract ## BACKGROUND Although temozolomide is active against recurrent malignant glioma, responses in many patients are modest and short‐lived. Temozolomide may prove more effective in combination with other agents. Therefore, combination oral chemotherapy for these patients is a particularly